[go: up one dir, main page]

MX2020014245A - Inhibidores de quinasas dependientes de ciclinas. - Google Patents

Inhibidores de quinasas dependientes de ciclinas.

Info

Publication number
MX2020014245A
MX2020014245A MX2020014245A MX2020014245A MX2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A
Authority
MX
Mexico
Prior art keywords
cyclin
inhibitors
dependent kinases
compounds
kinases
Prior art date
Application number
MX2020014245A
Other languages
English (en)
Inventor
Stephen W Kaldor
Eric A Murphy
Toufike Kanouni
Lee D Arnold
John Tyhonas
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of MX2020014245A publication Critical patent/MX2020014245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de quinasas dependientes de ciclinas (CDK), composiciones farmacéuticas que comprenden dichos compuestos y métodos para su utilización en el tratamiento de enfermedades.
MX2020014245A 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas. MX2020014245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862691879P 2018-06-29 2018-06-29
PCT/US2019/039959 WO2020006497A1 (en) 2018-06-29 2019-06-28 Inhibitors of cyclin-dependent kinases

Publications (1)

Publication Number Publication Date
MX2020014245A true MX2020014245A (es) 2021-05-12

Family

ID=68985220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014245A MX2020014245A (es) 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas.

Country Status (14)

Country Link
US (2) US10894788B2 (es)
EP (1) EP3813819A4 (es)
JP (1) JP2021529740A (es)
KR (1) KR20210040368A (es)
CN (1) CN112638373A (es)
AR (1) AR115646A1 (es)
AU (1) AU2019291935A1 (es)
BR (1) BR112020026748A2 (es)
CA (1) CA3104131A1 (es)
IL (1) IL279791A (es)
MX (1) MX2020014245A (es)
SG (1) SG11202013175SA (es)
TW (1) TW202016094A (es)
WO (1) WO2020006497A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
MX2020014245A (es) 2018-06-29 2021-05-12 Kinnate Biopharma Inc Inhibidores de quinasas dependientes de ciclinas.
JP7608342B2 (ja) 2018-10-01 2025-01-06 ウィンターミュート バイオメディカル，インク． 治療用組成物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021011796A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2021138215A1 (en) * 2019-12-31 2021-07-08 Kinnate Biopharma Inc. Treatment of cancer with cdk12/13 inhibitors
CN116113406B (zh) * 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL310368A (en) 2021-08-18 2024-03-01 Chemocentryx Inc Arylsulfonyl(hydroxy)piperidines as CCR6 inhibitors
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
TW202329937A (zh) * 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN119677729A (zh) * 2022-08-08 2025-03-21 英矽智能科技知识产权有限公司 细胞周期蛋白依赖性激酶(cdk)12和/或cdk13抑制剂及其用途
WO2025167975A1 (en) * 2024-02-07 2025-08-14 Insilico Medicine Ip Limited Crystalline cyclin-dependent kinase (cdk) 12 and/or cdk13 inhibitor and uses thereof
WO2025167978A1 (en) * 2024-02-07 2025-08-14 Insilico Medicine Ip Limited Cyclin-dependent kinase (cdk) 12 and/or cdk13 inhibitor combinations and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602209A1 (en) * 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
CN103958502B (zh) 2011-08-04 2016-02-10 阵列生物制药公司 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
US20140309184A1 (en) 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057954A2 (en) 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10040759B2 (en) * 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
SI3302448T1 (sl) 2015-06-04 2024-03-29 Aurigene Oncology Limited Substituirani heterociklični derivati kot inhibitorji cdk
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016283105C1 (en) * 2015-06-26 2023-02-02 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
GB201605126D0 (en) 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
JP7258748B2 (ja) * 2016-11-22 2023-04-17 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
CA3047136A1 (en) * 2016-12-19 2018-06-28 Isocure Biosciences Inc. Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715342D0 (en) 2017-09-22 2017-11-08 Univ Nottingham Compounds
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
MX2020014245A (es) 2018-06-29 2021-05-12 Kinnate Biopharma Inc Inhibidores de quinasas dependientes de ciclinas.
WO2021011796A1 (en) 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
WO2021138215A1 (en) 2019-12-31 2021-07-08 Kinnate Biopharma Inc. Treatment of cancer with cdk12/13 inhibitors

Also Published As

Publication number Publication date
US11390618B2 (en) 2022-07-19
BR112020026748A2 (pt) 2021-03-30
CN112638373A (zh) 2021-04-09
KR20210040368A (ko) 2021-04-13
JP2021529740A (ja) 2021-11-04
CA3104131A1 (en) 2020-01-02
TW202016094A (zh) 2020-05-01
US10894788B2 (en) 2021-01-19
SG11202013175SA (en) 2021-01-28
AU2019291935A1 (en) 2021-02-04
IL279791A (en) 2021-03-01
EP3813819A4 (en) 2022-08-17
AR115646A1 (es) 2021-02-10
US20210130340A1 (en) 2021-05-06
EP3813819A1 (en) 2021-05-05
US20200024266A1 (en) 2020-01-23
WO2020006497A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX2025002487A (es) Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
ZA202204284B (en) Inhibitors of raf kinases
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2023002507A (es) Inhibidores de cd73.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12019502646A1 (en) Pyrazole magl inhibitors
BR112018071585A2 (pt) formulações de um inibidor de lsd1
WO2020140054A8 (en) Cyclin-dependent kinase inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
ZA202204941B (en) Cd73 inhibitors
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2019014042A (es) Inhibidores pirazolicos de magl.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020000135A (es) Nuevos compuestos de quinolinona.